1. Articles in category: Regulation

    1-15 of 15
    1. Anti-cancer effect of oncolytic adenovirus-armed shRNA targeting MYCN gene on doxorubicin-resistant neuroblastoma cells.

      Anti-cancer effect of oncolytic adenovirus-armed shRNA targeting MYCN gene on doxorubicin-resistant neuroblastoma cells.

      Biochem Biophys Res Commun. 2017 Jul 12;:

      Authors: Li Y, Zhuo B, Yin Y, Han T, Li S, Li Z, Wang J

      Abstract Chemotherapy is one of the few effective choices for patients with neuroblastoma. However, the development of muti-drug resistance (MDR) to chemotherapy is a major obstacle to the effective treatment of advanced or recurrent neuroblastoma.

      Read Full Article
    2. γδTFH cells promote B cell maturation and antibody production in neuroblastoma.

      γδTFH cells promote B cell maturation and antibody production in neuroblastoma.

      BMC Immunol. 2017 Jul 07;18(1):36

      Authors: Mou W, Han W, Ma X, Wang X, Qin H, Zhao W, Ren X, Chen X, Yang W, Cheng H, Wang X, Zhang H, Ni X, Wang H, Gui J

      Abstract BACKGROUND: Previous studies have shown that γδ TFH cells are capable of modulating antibody production in immunized and infected mouse model.

      Read Full Article
      Mentions: Antibody
    3. Upregulation of LYAR induces neuroblastoma cell proliferation and survival.

      Upregulation of LYAR induces neuroblastoma cell proliferation and survival.

      Cell Death Differ. 2017 Jul 07;:

      Authors: Sun Y, Atmadibrata B, Yu D, Wong M, Liu B, Ho N, Ling D, Tee AE, Wang J, Mungrue IN, Liu PY, Liu T

      Abstract The N-Myc oncoprotein induces neuroblastoma by regulating gene transcription and consequently causing cell proliferation.

      Read Full Article
    4. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.

      Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.

      Mol Ther. 2017 Jul 01;:

      Authors: Walker AJ, Majzner RG, Zhang L, Wanhainen K, Long AH, Nguyen SM, Lopomo P, Vigny M, Fry TJ, Orentas RJ, Mackall CL

      Read Full Article
      Mentions: ALK
    5. CFC1 is a cancer stemness-regulating factor in neuroblastoma.

      CFC1 is a cancer stemness-regulating factor in neuroblastoma.

      Oncotarget. 2017 Jun 13;:

      Authors: Chikaraishi K, Takenobu H, Sugino RP, Mukae K, Akter J, Haruta M, Kurosumi M, Endo TA, Koseki H, Shimojo N, Ohira M, Kamijo T

      Abstract BACKGROUND: Despite the use of aggressive therapy, survival rates among high-risk neuroblastoma (NB) patients remain poor. Cancer stem cells (CSCs) are considered to be critically involved in the recurrence and metastasis of NB and are isolated as NB spheres.

      Read Full Article
      Mentions: Metastasis
    6. The Transcription Regulator Krüppel-Like Factor 4 and Its Dual Roles of Oncogene in Glioblastoma and Tumor Suppressor in Neuroblastoma.

      The Transcription Regulator Krüppel-Like Factor 4 and Its Dual Roles of Oncogene in Glioblastoma and Tumor Suppressor in Neuroblastoma.

      For Immunopathol Dis Therap. 2016;7(1-2):127-139

      Authors: Ray SK

      Abstract The Krüppel-like factor 4 (KLF4) gene is located on chromosome 9q31.

      Read Full Article
    7. SAHA sensitizes neuroblastoma to paclitaxel by inhibiting TRP14-mediated autophagy.

      SAHA sensitizes neuroblastoma to paclitaxel by inhibiting TRP14-mediated autophagy.

      Cancer Sci. 2017 May 12;:

      Authors: Zhen Z, Yang K, Ye L, You Z, Chen R, Liu Y, He Y

      Abstract Paclitaxel is not as effective for neuroblastoma as most of the front-line chemotherapeutics due to drug resistance. This study explored the regulatory mechanism of paclitaxel-associated autophagy and potential solutions to paclitaxel resistance in neuroblastoma.

      Read Full Article
    8. MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.

      MicroRNA-149 is associated with clinical outcome in human neuroblastoma and modulates cancer cell proliferation through Rap1 independent of MYCN amplification.

      Biochimie. 2017 Apr 26;:

      Authors: Xu Y, Chen X, Lin L, Chen H, Yu S, Li D

      Abstract PURPOSE: We evaluated the clinical relevance of microRNA-149 (miR-149) in neuroblastoma (NB) and its functional roles in regulating NB proliferation in vitro.

      Read Full Article
      Mentions: MYCN
    9. YAP promotes tumorigenesis and cisplatin resistance in neuroblastoma.

      YAP promotes tumorigenesis and cisplatin resistance in neuroblastoma.

      Oncotarget. 2017 Mar 15;:

      Authors: Yang C, Tan J, Zhu J, Wang S, Wei G

      Abstract The transcriptional co-activator Yes-associated protein (YAP) is essential for Hippo pathway-driven tumorigenesis in various cancers. However, the expression and function of YAP in neuroblastoma remains elusive. Here, we show that YAP was highly expressed in Neuroblastoma (NB) and expression levels correlated with advanced tumor staging.

      Read Full Article
    10. Childhood cancers in Europe: progress has been made, but much remains to be done, says major report

      Childhood cancers in Europe: progress has been made, but much remains to be done, says major report

      Each year in Europe, 6,000 young people die from cancer, and two-thirds of those who survive suffer from treatment-related side effects. Although there has been considerable progress in the treatment of childhood cancers over the past few decades, and cancer in childhood is rare, these are major problems that need to be overcome, says a report from SIOPE, the European Society for Paediatric Oncology, launched at the 2015 European Cancer Conference today.

      https://www.europeancancercongress.org/Global/News/ECC-2015-News/2015/09/PR-26-SEP-Childhood-cancers-in-Europe

      Read Full Article
    1-15 of 15
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (1 articles) Antibody
    2. (1 articles) ALK
    3. (1 articles) MYCN
  4. General Informations in the News

    1. (1 articles) Treatment
  5. Treatments in the News

    1. (1 articles) Chemotherapy